Real-world clinical responses to selpercatinib in RET M918T-mutant medullary thyroid carcinoma
Abstract Background RET alterations, especially the M918T mutation, contribute to the development of aggressive medullary thyroid carcinoma (MTC). Selective RET inhibition has shown greater efficacy compared to VEGFR-targeting multikinase inhibitors (MKIs). Nevertheless, evidence from real-world set...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Springer
2026-04-01
|
| Rangatū: | Discover Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1007/s12672-026-04881-w |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|